Clinical Trials | VOTRIENT® (pazopanib) tablets
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial - Clinical Genitourinary Cancer
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer | SpringerLink
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research
Table 3 from A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar
Votrient - NPS MedicineWise
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer | SpringerLink
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
Votrient, pazopanib
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures - Spigel - 2018 -
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer | Future Oncology
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation | BMC Cancer
The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation | BMC Cancer
Votrient - NPS MedicineWise
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | Signal Transduction and Targeted Therapy
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer
Biomedicines | Free Full-Text | Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma | HTML
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
